ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

Skip to Content

Clinical Trial Details

ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

Objective

A081105, Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

E4512, A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

A151216, Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

EA5142, Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

IRB Protocol Number
ALCHEMIST A081105 E4512 EA5142 A151216

Clinical Trial Categories

  • Lung Cancer
Contact
NH Oncology Hematology Clinical Research Dept. at 603-224-2556

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000